| Literature DB >> 34128073 |
Calixto-Hope G Lucas1, Patrick Devine1,2, David A Solomon1, Caterina Giannini3, Guido Reifenberger4, Sonika Dahiya5, Dario Caccamo6, Arie Perry1,7.
Abstract
Anaplastic meningiomas can have a sarcomatous appearance on histology but true sarcomatous (metaplastic) differentiation is rare. These tumors follow an aggressive clinical course with recurrence and poor clinical outcomes. Due to significant overlap in morphology and immunohistochemical profiles, distinguishing between sarcomatous transformation of a meningioma and a true sarcoma can be challenging. Here, we outline potential diagnostic pitfalls and the utility of ancillary molecular testing in 3 patients diagnosed with sarcomatous meningiomas. We report loss of typical meningothelial markers in sarcomatous meningiomas. Ancillary molecular testing can support the diagnosis of sarcomatous meningioma when a molecular signature consistent with meningioma is seen, such as inactivation of the NF2 gene. Recognition of this rare transformation in meningioma can prevent a misdiagnosis of a primary sarcoma, whether sporadic or radiation-induced from prior treatment of a more classic meningioma.Entities:
Keywords: Anaplastic; Meningioma; Molecular; Neuropathology; Sarcomatous
Mesh:
Substances:
Year: 2021 PMID: 34128073 PMCID: PMC9432138 DOI: 10.1093/jnen/nlab053
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.148